Werewolf Therapeutics Inc
HOWL1.215USD
+0.055+4.74%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
54.46MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Werewolf Therapeutics Inc Unternehmen
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Unternehmensinformationen
BörsenkürzelHOWL
Name des UnternehmensWerewolf Therapeutics Inc
IPO-datumApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Anzahl der mitarbeiter46
WertpapierartOrdinary Share
GeschäftsjahresendeApr 30
Addresse200 Talcott Avenue
StadtWATERTOWN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02472
Telefon16179520555
Websitehttps://werewolftx.com/
BörsenkürzelHOWL
IPO-datumApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, May 14
Aktualisiert: Wed, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
19.93%
Venture Capital
14.89%
Hedge Fund
12.83%
Investment Advisor
9.66%
Research Firm
5.33%
Corporation
4.56%
Individual Investor
1.51%
Bank and Trust
0.08%
Family Office
0.02%
Other
31.19%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
157
30.87M
68.80%
-5.72M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
PFM Health Sciences, LP
2.51M
5.59%
-398.94K
-13.73%
Mar 31, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.48M
3.3%
-29.02K
-1.92%
Mar 31, 2025
Rubric Capital Management LP
1.33M
2.97%
--
--
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
DFA Dimensional US Core Equity Market ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
